FUZEON

LOE Approaching

enfuvirtide

NDASUBCUTANEOUSINJECTABLEPriority Review
Approved
Mar 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Clinical Trials (5)

NCT00937729N/ATerminated

Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules

Started Jun 2009
4 enrolled
HIV1 InfectionHIV Infections
NCT00615134Phase 2Completed

INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.

Started Jan 2008
29 enrolled
HIV Infections
NCT00529243Phase 3Completed

Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects

Started Sep 2007
52 enrolled
HIV Infections
NCT00488059Phase 4Terminated

A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients

Started Jun 2007
29 enrolled
HIV Infections
NCT00461266Phase 4Withdrawn

ESP Study: A Study to Assess the Effect of Adding Fuzeon (Enfuvirtide) to an Antiretroviral Regimen in Fuzeon-Naive Patients With Sustained HIV Viral Suppression.

Started Apr 2007
0
HIV Infections